SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001479290-23-000080
Filing Date
2023-06-20
Accepted
2023-06-20 16:25:04
Documents
1
Period of Report
2023-06-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_168729267524879.html 4  
1 FORM 4 wf-form4_168729267524879.xml 4 6784
  Complete submission text file 0001479290-23-000080.txt   8215
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, SUITE 1001 NASHVILLE TN 37203
Business Address
Kolaja Carey OConnor (Reporting) CIK: 0001848717 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36297 | Film No.: 231025433